/C O R R E C T I O N -- Halozyme Therapeutics, Inc./

In the news release, Halozyme To Host Third Quarter 2015 Financial Results Conference Call, issued 19-Oct-2015 by Halozyme Therapeutics, Inc. over PR Newswire, we are advised by the company that the date of the Quarterly Update Conference Call webcast should be "Monday, November 9 at 4:30 p.m. ET/1:30 p.m. PT" rather than "Tuesday, November 10 at 4:30 p.m. ET/1:30 p.m. PT" as originally issued. The complete, corrected release follows:

Halozyme To Host Third Quarter 2015 Financial Results Conference Call

SAN DIEGO, Oct. 19, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2015 on Monday, November 9 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2015.

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the call. To access the webcast and additional documents related to the call, please visit www.halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. The live call may be accessed by calling (877) 410-5657 (domestic callers) or (334) 323-7224 (international callers) using passcode 769890. A telephone replay will be available after the call by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay ID number 75162222.

About HalozymeHalozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contact:Jim MazzolaHalozyme Therapeutics858-704-8122[email protected]

Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/halozyme-to-host-third-quarter-2015-financial-results-conference-call-300162219.html

SOURCE Halozyme Therapeutics, Inc.